Methods and compositions for treating sarcoma
Administering anti-IL-23p19 antibodies like tildrakizumab targets the IL-23 pathway to treat advanced sarcomas, providing a promising alternative to existing immunotherapies by inhibiting tumor growth and improving patient outcomes.
Patent Information
- Application Number
- PCT/US2026/027788
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-12
- Filing Date
- 2026-05-12
- Publication Date
- 2026-11-19
AI Technical Summary
Patients with advanced sarcomas, including osteosarcomas and soft tissue sarcomas, lack effective therapeutic options, and immune checkpoint inhibitors targeting the PD-1/PD-L1 axis have shown limited efficacy, highlighting the need for alternative immune suppressor pathway-targeting therapies.
Administering a pharmaceutical composition comprising an anti-IL-23p19 antibody or its antigen binding fragment, such as tildrakizumab, to treat sarcomas, particularly advanced osteosarcoma and soft tissue sarcoma, by targeting the IL-23 pathway.
The anti-IL-23p19 antibody therapy demonstrates potential in inhibiting tumor growth and improving patient outcomes in sarcoma models, offering a novel approach beyond current immunotherapy strategies.
Smart Images

Figure IMGF000029_0001_TABLE 
Figure IMGF000030_0001_TABLE 
Figure IMGF000031_0001_TABLE
Abstract
Description
PCT / US2026 / 027788 12 May 2026 (12.05.2026)Attorney Ref. No. 0094-0218W01METHODS AND COMPOSITIONS FOR TREATING SARCOMAREFERENCE TO AN ELECTRONIC SEQUENCE LISTING
[0001] This application is being filed electronically and includes an electronically submitted sequence listing. The sequence listing is entitled "25-0824-US-PRO-Sequence-Listing.xml" and was created on May 12, 2025, and has a size of 8,234 bytes. The sequence listing contained in this .xml file is part of the specification and is herein incorporated by reference in its entirety.FIELD OF THE DISCLOSURE
[0002] The disclosure relates to methods of treating sarcoma in a patient in need thereof, comprising administering a pharmaceutical composition to the patient, wherein the pharmaceutical composition comprises an anti-IL-23pl9 antibody or antigen binding fragment thereof. The disclosure also relates to pharmaceutical compositions of an anti-IL-23pl9 antibody or antigen binding fragment thereof for the treatment of sarcoma in a patient in need thereof. The disclosure further relates to the use of an anti-IL-23pl9 antibody or antigen binding fragment thereof for the manufacture of a medicament for treating sarcoma in a patient in need thereof. The disclosure further relates to methods, compositions, or uses wherein the anti-IL-23pl9 antibody or antigen binding fragment thereof is the anti-IL-23pl9 antibody huml3B8-b. The disclosure further relates to methods, compositions, or uses wherein the sarcoma is advanced osteosarcoma or soft tissue sarcoma.BACKGROUND
[0003] Patients with advanced sarcomas, including osteosarcomas and soft tissue sarcomas, remain incurable with few therapeutic options in the advanced disease setting. Recent advances in immunotherapy in other solid tumours highlight the untapped potential of using immune targeted strategies in sarcoma (Kansara et al., 2014). To date, however, trials of immune checkpoint inhibitors (ICI) targeting PD-1 / PD-L1 axis have been largely disappointing in sarcoma (SARC028 trial) (Tawbi et al., 2017), and allude to the existence of other immune suppressor pathways being active and potentially targetable.
[0004] Interleukin-23 (IL-23) is a proinflammatory cytokine belonging to the IL-12 cytokine family. IL-23 is a heterodimeric cytokine consisting of a unique pl9 subunit and a common p40 subunit shared with IL-12. It is mainly produced by activated myeloid cells, and signals through a heterodimeric IL-23 receptor complex consisting of a unique IL-23PCT / US2026 / 027788 12 May 2026 (12.05.2026)Attorney Ref. No. 0094-0218W01receptor (IL23R) paired with IL-12RP1. Soon after its discovery, IL-23 was recognized as a key driver of autoimmunity in mouse models and human diseases. This has been commonly attributed to the ability of IL-23 to polarize and activate Thl7 cells, a subset of T cells that has been identified as having a central role in autoimmunity. The IL-23 cytokine and associated signaling pathway has been implicated in several diseases and conditions including autoimmune disorders, chronic inflammatory disorders, psoriasis, psoriatic arthritis, and obesity.
[0005] In addition, high expression of IL-23 relative to normal adjacent tissue has been reported in many human cancer types and is associated with increased tumour incidence and growth (Langowski et al., 2006; Langowski et al., 2007). However, the use of anti-IL-23 therapy in human cancer has not been examined in clinical studies to date. Thus, there is a need in the art for additional compositions and methods for the treatment of sarcoma, including advanced osteosarcoma and soft tissue sarcoma, wherein such compositions and methods involve the use of anti-IL-23 therapy.SUMMARY
[0006] The disclosure provides a method of treating sarcoma in a patient in need thereof, comprising administering a pharmaceutical composition to the patient, wherein the pharmaceutical composition comprises an anti-IL-23pl9 antibody or antigen binding fragment thereof.
[0007] The disclosure also provides a pharmaceutical composition comprising an anti-IL-23pl9 antibody or antigen binding fragment thereof for use in the treatment of sarcoma in a patient in need thereof.
[0008] The disclosure further provides the use of an anti-IL-23pl9 antibody or antigen binding fragment thereof for the manufacture of a medicament for treating sarcoma in a patient in need thereof.
[0009] The disclosure further provides a method of treating sarcoma in a patient in need thereof, comprising administering a pharmaceutical composition to the patient, wherein the pharmaceutical composition comprises the anti-IL-23pl9 antibody huml3B8-b.
[0010] The disclosure further provides a pharmaceutical composition comprising the anti-IL-23pl9 antibody huml3B8-b for use in the treatment of sarcoma in a patient in need thereof.
[0011] The disclosure further provides the use of the anti-IL-23pl9 antibody huml3B8-b for the manufacture of a medicament for treating sarcoma in a patient in need thereof.PCT / US2026 / 027788 12 May 2026 (12.05.2026)Attorney Ref. No. 0094-0218W01
[0012] The disclosure further provides methods, pharmaceutical compositions, or medicaments for treating sarcoma in a patient in need thereof, wherein the sarcoma is advanced osteosarcoma or soft tissue sarcoma.
[0013] These and other features and advantages of the present disclosure will be more fully understood from the following detailed description taken together with the accompanying claims. It is noted that the scope of the claims is defined by the recitations therein and not by the specific discussion of features and advantages set forth in the present description.BRIEF DESCRIPTIONS OF THE DRAWINGS
[0014] The following detailed description of the embodiments of the present disclosure can be best understood when read in conjunction with the following drawings.
[0015] FIG. 1 depicts a schema of the sarcoma research study.
[0016] FIG. 2A is a forest plot depicting wildtype and gene-targeted mice injected with45Ca intrapritoneally once per week for 4 consecutive weeks. Tumor growth was monitored over 2 years. Hazard ratio (log rank) 95% confidence interval, Mantel-Cox test for significance compared to wildtype (n=14-30).
[0017] FIG. 2B depicts a Kaplan Meier plot of IL-23 high and IL-23 low mice over time in months. IL23 ' mice were significantly protected from the development of45Ca-induced osteosarcomas compared to wildtype mice (pO.OOOl).
[0018] FIG. 2C depicts the tumor size (cm2) over time in days of wildtype and IL23 ' cohorts after mice were injected with 400 pg methylcholanthrene (MCA) and monitored for up to 250 days. IL23 ' mice were more resistant to tumor formation in the MCA model of fibrosarcoma.
[0019] FIG. 2D represents in situ hybridization showing focal staining of IL-23 in primary human osteosarcomas compared to bone.
[0020] FIG. 2E depicts the relative expression of IL23A and IL12A transcript levels compared to normal human bone using quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) in an independent cohort with corresponding survival data (n=33).
[0021] FIG. 2F depicts a Kaplan Meier plot of IL23 low and IL23A high mice. High IL23A expression (>8 fold) correlated with worse overall survival in human osteosarcoma (p=0.042).PCT / US2026 / 027788 12 May 2026 (12.05.2026)Attorney Ref. No. 0094-0218W01
[0022] FIG. 2G represents the mean tumor volume (mm3) ± SEM over time in days of mice injected with 106cells OS18. Mice with tumors at 100 mm3were treated with aIL23 or control antibody (AGP) at 500 pg / mouse on days 1, 3, 5, 7, 9, 12, 16, and 21.
[0023] FIG. 2H depicts the mean tumor volume (mm3) ± SEM over time in days of mice injected with 106cells OS18. Mice with tumors at 100 mm3were treated with aIL23 and liposomal DOX (5 mg / kg / week), control antibody (AGP) at 500 pg / mouse and liposomal DOX (5 mg / kg / week), or control antibody (AGP) at 500 pg / mouse only (n=6 / cohort).DETAILED DESCRIPTION
[0024] The disclosure relates to methods of treating sarcoma in a patient in need thereof, comprising administering a pharmaceutical composition to the patient, wherein the pharmaceutical composition comprises an anti-IL-23pl9 antibody or antigen binding fragment thereof. The disclosure also relates to pharmaceutical compositions of an anti-IL-23pl9 antibody or antigen binding fragment thereof for the treatment of sarcoma in a patient in need thereof. The disclosure further relates to the use of an anti-IL-23pl9 antibody or antigen binding fragment thereof for the manufacture of a medicament for treating sarcoma in a patient in need thereof.
[0025] The disclosure relates to methods, compositions, or uses wherein the anti-IL-23pl9 antibody or antigen binding fragment thereof is the anti-IL-23pl9 antibody huml3B8-b. The disclosure also relates to methods, compositions, or uses wherein the sarcoma is advanced osteosarcoma or soft tissue sarcoma.
[0026] Unless otherwise required by context, the use of singular terms in the disclosure shall include pluralities and plural terms shall include the singular. For example, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. It should be understood that the terms "a" and "an" as used herein refer to "one or more" of the enumerated components unless otherwise indicated or dictated by its context. The use of the alternative (e.g., "or") should be understood to mean either one, both, or any combination thereof of the alternatives unless otherwise indicated.
[0027] As used in the disclosure, any concentration range, percentage range, ratio range, or integer range is to be understood to include the value of any integer within the recited range and, when appropriate, fractions thereof (such as one tenth and one hundredth of an integer), unless otherwise indicated. Ranges provided herein are understood to be shorthand for all of the values within the range. For example, a range of 1 to 25 is understood to include anyPCT / US2026 / 027788 12 May 2026 (12.05.2026)Attorney Ref. No. 0094-0218W01number, combination of numbers, or sub-range from the group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25.
[0028] The terms "about" and "approximately," as used herein, mean within an acceptable error range for the particular value as determined by one of ordinary skill in the art, which will depend in part on how the value is measured or determined, z.e., the limitations of the measurement system. For example, "about" can mean within 3 or more than 3 standard deviations, per the practice in the art. Alternatively, "about" can mean a range of up to 20%, preferably up to 10%, more preferably up to 5%, and more preferably still up to 1% of a given value. Alternatively, and particularly with respect to biological systems or processes, the term "about" can mean within an order of magnitude, preferably within 5-fold, and more preferably within 2-fold, of a value. With regard to the administration of an anti-IL-23pl9 antibody, the anti-IL-23pl9 antibody huml3B8-b, or an antigen binding fragment thereof as described herein, the term "about" when used with respect to a number of weeks means the number of weeks + / - 7 days.
[0029] It is noted that terms like "preferably," "commonly," and "typically" are not used herein to limit the scope of the claimed subject matter or to imply that certain features are critical, essential, or even important to the structure or function of the claimed subject matter. Rather, these terms are merely intended to highlight alternative or additional features that can or cannot be used in a particular embodiment of the present disclosure.
[0030] It is noted that the term "substantially," as used herein, represents the inherent degree of uncertainty that can be attributed to any quantitative comparison, value, measurement, or other representation. The term "substantially" is also used herein to represent the degree by which a quantitative representation can vary from a stated reference without resulting in a change in the basic function of the subject matter at issue.
[0031] Unless expressly specified otherwise, the term "comprising" is used in the context of the present disclosure to indicate that further members may optionally be present in addition to the members of the list introduced by "comprising." It is, however, contemplated that the term "comprising" can encompass the possibility of no further members being present.
[0032] The terms "consisting essentially of' or "consists essentially," as used herein, allow for the presence of more than that which is recited so long as basic or novel characteristics of that which is recited are not changed by the presence of more than that which is recited.PCT / US2026 / 027788 12 May 2026 (12.05.2026)Attorney Ref. No. 0094-0218W01
[0033] Unless otherwise indicated in the disclosure, all technical and scientific terms used in the disclosure shall be understood to have the meaning commonly understood by one of ordinary skill in the art.
[0034] The term "antibody," as used herein, refers to a protein that is capable of recognizing and specifically binding to an antigen. Ordinary or conventional mammalian antibodies comprise a tetramer, which is typically composed of two identical pairs of polypeptide chains, each pair consisting of one "light" chain (typically having a molecular weight of about 25 kDa) and one "heavy" chain (typically having a molecular weight of about 50-70 kDa). The terms "heavy chain" and "light chain," as used herein, refer to any immunoglobulin polypeptide having sufficient variable domain sequence to confer specificity for a target antigen. The amino-terminal portion of each light and heavy chain typically includes a variable domain of about 100 to 110 or more amino acids that typically is responsible for antigen recognition. The carboxyl-terminal portion of each chain typically defines a constant domain responsible for effector function. Thus, in a naturally occurring antibody, a full-length heavy chain immunoglobulin polypeptide includes a variable domain (VH) and three constant domains (CHI, CH2, and Cm) and a hinge region between CHI and CH2, wherein the VH domain is at the amino-terminus of the polypeptide and the CH3 domain is at the carboxyl-terminus, and a full-length light chain immunoglobulin polypeptide includes a variable domain (VL) and a constant domain (CL), wherein the VL domain is at the amino-terminus of the polypeptide and the CL domain is at the carboxyl-terminus.
[0035] Within full-length light and heavy chains, the variable and constant domains typically are joined by a "J" region of about 12 or more amino acids, with the heavy chain also including a "D" region of about 10 more amino acids. The variable regions of each light / heavy chain pair typically form an antigen binding site. The variable domains of naturally occurring antibodies typically exhibit the same general structure of relatively conserved framework regions (FR) joined by three hypervariable regions, also called complementarity determining regions or CDRs. The CDRs from the two chains of each pair typically are aligned by the framework regions, which may enable binding to a specific epitope. From the amino-terminus to the carboxyl-terminus, both light and heavy chain variable domains typically comprise the domains FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4.
[0036] The term "antigen binding fragment" as used herein refers to a portion of an intact antibody and / or refers to the antigenic determining variable domains of an intact antibody. It is known that the antigen binding function of an antibody can be performed by fragments of aPCT / US2026 / 027788 12 May 2026 (12.05.2026)Attorney Ref. No. 0094-0218W01full-length antibody. Examples of antibody fragments include, but are not limited to, Fab, Fab', F(ab')2, and Fv fragments, linear antibodies, single chain antibodies, diabodies, and multispecific antibodies formed from antibody fragments.
[0037] In some embodiments of the compositions and methods of the disclosure, the anti-IL-23pl9 antibody or antigen binding fragment thereof is the anti-IL-23pl9 antibody huml3B8-b, or tildrakizumab. The term "tildrakizumab," as used herein, refers to a humanized anti-IL-23pl9 monoclonal antibody, also known as SCH 900222 or MK-3222. Tildrakizumab is a high-affinity (297 picomolar [pM]) humanized immunoglobulin Gl / kappa (IgGl / K) antibody that specifically binds to the pl9 protein of the IL-23 heterodimer but does not bind human IL-12 (IL-12 / 23p40 and IL12p35 heterodimer) or human IL-12 / 23p40. The efficacy and safety of tildrakizumab in the treatment of patients with moderate-to-severe plaque psoriasis has been demonstrated in two Phase 3 studies (P010 and P011) (Beck et al., 2018; Reich etal., 2017). The efficacy and safety of tildrakizumab was also demonstrated in a randomised, double-blind, placebo-controlled, multiple-dose, phase 2b study in patients with active psoriatic arthritis (NCT02980692) (Mease et al., 2019). Results from these studies demonstrated that tildrakizumab was generally well tolerated with a low incidence of drug-related adverse events (AEs) and AEs leading to discontinuation of the study medication. The safety profile for tildrakizumab has been shown to be favourable; serious adverse events that occur in 1% of patients are upper respiratory infections, injection site reactions, and diarrhoea in previously reported placebo controlled trials (Reich etal., 2017; Reich et al., 2019; U.S. Food and Drug Administration, ILUMYA prescribing information).
[0038] Tildrakizumab pharmacokinetics increases proportionally over a dose range from 50 mg to 200 mg (0.5 to 2 times the approved recommended dosage) following subcutaneous administration in subjects with plaque psoriasis. Steady-state concentrations were achieved by Week 16 following subcutaneous administration of tildrakizumab at Weeks 0, 4, and every 12 weeks thereafter. At the 100 mg dose at Week 16, the mean (± SD) steady-state trough concentrations ranged from 1.22 ± 0.94 mcg / mL to 1.47 ± 1.12 mcg / mL. The geometric mean (CV%) steady-state Cmax was 8.1 mcg / mL (34%). The absolute bioavailability of tildrakizumab was estimated to be 73-80% following subcutaneous injection. The peak concentration (Cmax) was reached by approximately 6 days.
[0039] In some embodiments of the compositions and methods of the disclosure, the anti-IL-23pl9 antibody tildrakizumab can refer to ILUMYA®. ILUMYA® is administered by subcutaneous injection at a recommended dosage of 100 mg at weeks 0, 4, and every 12 weeks thereafter. In some embodiments, tildrakizumab is formulated in a 1 mL single-dosePCT / US2026 / 027788 12 May 2026 (12.05.2026)Attorney Ref. No. 0094-0218W01prefilled syringe containing 100 mg of tildrakizumab (z.e., 100 mg / mL). In some embodiments, ILUMYA® (tildrakizumab-asmn) injection, for subcutaneous use, is a sterile, clear to slightly opalescent, colorless to slightly yellow solution. ILUMYA® is supplied in a single-dose prefilled syringe with a glass barrel and 29-gauge fixed, 1 / 2-inch needle. In some embodiments, tildrakizumab can be formulated in: L-histidine, L-histidine hydrochloride monohydrate, polysorbate 80, and / or sucrose, in Water for Injection, with a pH of 5.7-6.3. In some embodiments, tildrakizumab is formulated in a 1 mL single-dose prefilled syringe containing 100 mg of tildrakizumab-asmn formulated in: L-histidine (0.495 mg), L-histidine hydrochloride monohydrate (1.42 mg), polysorbate 80 (0.5 mg), sucrose (70.0 mg), and Water for Injection, USP with a pH of 5.7-6.3.
[0040] In some embodiments of the compositions and methods of the disclosure, the anti-IL-23pl9 antibody huml3B8-b (tildrakizumab) comprises a light chain polypeptide comprising the amino acid sequence of SEQ ID NO: 1 and a heavy chain polypeptide comprising the amino acid sequence of SEQ ID NO: 2, and is disclosed in U.S. Patent Nos.8,404,813 and 8,293,883, the disclosures of each of which are hereby incorporated by reference in their entireties. In some embodiments, the anti-IL-23pl9 antibody huml3B8-b or an antigen-binding fragment thereof comprises a heavy chain variable domain and a light chain variable domain, wherein the heavy chain variable domain comprises CDR1, CDR2, and CDR3 sequences of the amino acid sequences of SEQ ID NOs: 3-5, and wherein the light chain variable domain comprises CDR1, CDR2, and CDR3 sequences of the amino acid sequences of SEQ ID NOs: 6-8.
[0041] Huml3B8-b Light Chain (SEQ ID NO: 1) DIQMTQSPSSLSASVGDRVTITCRTSENIYSYLAWYQQKPGKAPKLLIYNAKTLAEGVPSRF SGSGSGTDFTLTISSLQPEDFATYYCQHHYGIPFTFGQGTKVEIKRTVAAPSVFIFPPSDEQ LKSGTASWCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADY EKHKVYACEVTHQGLSSPVTKSFNRGEC
[0042] Huml3B8-b Heavy Chain (SEQ ID NO: 2) QVQLVQSGAEVKKPGASVKVSCKASGYIFITYWMTWVRQAPGQGLEWMGQIFPASGSADYNE KFEGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARGGGGFAYWGQGTLVTVSSASTKGPSV FPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSWT VPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKD TLMISRTPEVTCVWDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRWSVLTVLHQ DWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPCT / US2026 / 027788 12 May 2026 (12.05.2026)Attorney Ref. No. 0094-0218W01PSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNH YTQKSLSLSPGK
[0043] Huml3B8-b Heavy Chain CDR1 (SEQ ID NO: 3)GYIFITYWMT
[0044] Huml3B8-b Heavy Chain CDR2 (SEQ ID NO: 4)QI FPASGSADYNEKFE
[0045] Huml3B8-b Heavy Chain CDR3 (SEQ ID NO: 5)GGGGFAY
[0046] Huml3B8-b Light Chain CDR1 (SEQ ID NO: 6)RTSENIYSYLA
[0047] Huml3B8-b Light Chain CDR2 (SEQ ID NO: 7)NAKTLAE
[0048] Huml3B8-b Light Chain CDR3 (SEQ ID NO: 8)QHHYGIPFT
[0049] The terms "subject" and "patient," as used herein, are interchangeable. In some embodiments of the compositions or methods of the disclosure, the patient is a mammal. In some embodiments of the compositions or methods of the disclosure, the patient is a human. In some embodiments of the compositions or methods of the disclosure, the human patient is at least 18 years old.
[0050] The terms "disease," "disorder," and "condition," as used herein, are interchangeable and refer to diseases or disorders that can be treated using an anti-IL-23pl9 antibody, anti-IL-23pl9 antibody huml3B8-b, or antigen binding fragment thereof of the disclosure. Such diseases or disorders include chronic and acute diseases or disorders, including those pathological conditions that predispose a patient to the disease or disorder in question.
[0051] In some embodiments of the compositions or methods of the disclosure, the disease that can be treated using an anti-IL-23pl9 antibody, anti-IL-23pl9 antibody huml3B8-b, or antigen binding fragment thereof is sarcoma. In some embodiments, the sarcoma is advanced osteosarcoma or soft tissue sarcoma.
[0052] The terms "treatment" or "treat," as used herein, refer to both therapeutic treatment and prophylactic or preventative measures. Those in need of treatment include patients having sarcoma. Those in need of treatment include patients having advanced osteosarcoma or soft tissue sarcoma.
[0053] The terms "administration" or "administering," as used herein, refer to providing, contacting, and / or delivering an anti-IL-23pl9 antibody, anti-IL-23pl9 antibody hum!3B8-b,PCT / US2026 / 027788 12 May 2026 (12.05.2026)Attorney Ref. No. 0094-0218W01or antigen binding fragment thereof by any appropriate route to achieve the desired effect. Administration may include, but is not limited to, oral, sublingual, parenteral (e.g., intravenous, subcutaneous, intracutaneous, intramuscular, intraarticular, intraarterial, intrasynovial, intrastemal, intrathecal, intralesional, or intracranial injection), transdermal, topical, buccal, rectal, vaginal, nasal, ophthalmic, via inhalation, and implants.
[0054] In some embodiments of the compositions or methods of the disclosure, the anti-IL-23pl9 antibody, anti-IL-23pl9 antibody huml3B8-b, or antigen binding fragment thereof is administered via intravenous infusion.
[0055] In some embodiments of the compositions or methods of the disclosure, the anti-IL-23pl9 antibody, anti-IL-23pl9 antibody huml3B8-b, or antigen binding fragment thereof is administered subcutaneously. In some embodiments, the anti-IL-23pl9 antibod, anti-IL-23pl9 antibody huml3B8-b, or antigen binding fragment thereof is administered to the patient by subcutaneous injection.
[0056] The terms "pharmaceutical composition" or "therapeutic composition," as used herein, refer to a compound or composition capable of inducing a desired therapeutic effect when properly administered to a patient. In some embodiments, the disclosure provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of an anti-IL-23pl9 antibody, anti-IL-23pl9 antibody huml3B8-b, or antigen binding fragment thereof.
[0057] Pharmaceutical compositions comprising tildrakizumab, either alone or in combination with prophylactic agents, therapeutic agents, and / or pharmaceutically acceptable carriers are provided. The pharmaceutical compositions comprising tildrakizumab provided herein are for use in, but not limited to, preventing, treating, managing, or ameliorating a disease or disorder or one or more symptoms thereof. The formulation of pharmaceutical compositions, either alone or in combination with prophylactic agents, therapeutic agents, and / or pharmaceutically acceptable carriers, is known to one skilled in the art.
[0058] The terms "pharmaceutically acceptable carrier" or "physiologically acceptable carrier," as used herein, refer to one or more formulation materials suitable for accomplishing or enhancing the delivery of an anti-IL-23pl9 antibody, anti-IL-23pl9 antibody huml3B8-b, or antigen binding fragment thereof.
[0059] The term "therapeutically effective amount" as applied to a dose or amount refers to the quantity of a compound or pharmaceutical composition that is sufficient to result in a desired effect upon administration to a patient in need thereof. As used herein, with respect to pharmaceutical compositions comprising an anti-IL-23pl9 antibody, the anti-IL-23pl9PCT / US2026 / 027788 12 May 2026 (12.05.2026)Attorney Ref. No. 0094-0218W01antibody huml3B8-b, or antigen binding fragment thereof, the term "therapeutically effective amount" also refers to the dose of a compound or pharmaceutical composition that is sufficient to produce an effective response upon administration to a patient. In some embodiments of the compostions or methods of the disclosure, a therapeutically effective amount of the anti-IL-23pl9 antibody huml3B8-b refers to a dose of about 100 mg, about 125 mg, about 150 mg, about 175 mg, or about 200 mg. In one embodiment, the therapeutically effective amount of huml3B8-b refers to a dose of 100 mg. In another embodiment, the therapeutically effective amount of huml3B8-b refers to a dose of 200 mg.
[0060] In some embodiments of the compositions or methods of the disclosure, the dose of the anti-IL-23pl9 antibody, the anti-IL-23pl9 antibody huml3B8-b, or antigen binding fragment thereof will vary depending, in part, upon the size (e.g., body weight) and condition (i.e., the age and general health) of the patient. In some embodiments, the patient is administered one or more doses of the anti-IL-23pl9 antibody, the anti-IL-23pl9 antibody huml3B8-b, or antigen binding fragment thereof wherein the dose is 100 mg, 120 mg, 140 mg, 160 mg, 180 mg, 200 mg, or more than 200 mg. In some embodiments, the first dose and the subsequent doses of the anti-IL-23pl9 antibody, the anti-IL-23pl9 antibody huml3B8-b, or antigen binding fragment thereof are the same. In some embodiments, the first dose and the subsequent doses of the anti-IL-23pl9 antibody, the anti-IL-23pl9 antibody huml3B8-b, or antigen binding fragment thereof are different.
[0061] In some embodiments of the compositions or methods of the disclosure, the pharmaceutical composition comprising an anti-IL-23pl9 antibody, the anti-IL-23pl9 antibody huml3B8-b, or an antigen binding fragment thereof is administered to the patient using a prefilled syringe (PFS) or auto-injector device. In some embodiments, the pharmaceutical composition comprising an anti-IL-23pl9 antibody, the anti-IL-23pl9 antibody huml3B8-b, or an antigen binding fragment thereof is administered to the patient using an intravenous (IV) bag. In some embodiments, the pharmaceutical composition comprising an anti-IL-23pl9 antibody, the anti-IL-23pl9 antibody huml3B8-b, or an antigen binding fragment thereof is administered to the patient using a prefilled ampule or single dose vial. In some embodiments, the pharmaceutical composition comprising an anti-IL-23pl9 antibody, the anti-IL-23pl9 antibody huml3B8-b, or an antigen binding fragment thereof is administered to the patient using a wearable device.
[0062] In some embodiments of the compositions or methods of the disclosure, the prefilled syringe or auto-injector device, intravenous (IV) bag, prefilled ampule, single dose vial, or wearable device comprises a pharmaceutical composition comprising an anti-IL-PCT / US2026 / 027788 12 May 2026 (12.05.2026)Attorney Ref. No. 0094-0218W0123pl9 antibody, the anti-IL-23pl9 antibody huml3B8-b, or an antigen binding fragment thereof, wherein the concentration of the anti-IL-23pl9 antibody, the anti-IL-23pl9 antibody huml3B8-b, or an antigen binding fragment thereof is 100 mg / mL, 125 mg / mL, 150 mg / mL, 175 mg / mL, or 200 mg / mL. In some embodiments, the concentration of the anti-IL-23pl9 antibody, the anti-IL-23pl9 antibody huml3B8-b, or an antigen binding fragment thereof is 125 mg / mL.
[0063] In some embodiments of the compositions or methods of the disclosure, the anti-IL-23pl9 antibody, anti-IL-23pl9 antibody huml3B8-b, or antigen binding fragment thereof is administered using an onbody injector device (OB ID). In one embodiment, the OB ID includes anti -divergence technology. An OB ID offers the subject convenience and facilitates cartridge use.
[0064] In some embodiments of the compositions or methods of the disclosure, the anti-IL-23pl9 antibody, anti-IL-23pl9 antibody huml3B8-b, or antigen binding fragment thereof is administered to the patient about every week, about every 2 weeks, about every 3 weeks, about every 4 weeks, about every 5 weeks, about every 6 weeks, about every 7 weeks, about every 8 weeks, about every 9 weeks, about every 10 weeks, about every 11 weeks, about every 12 weeks, about every 13 weeks, about every 14 weeks, about every 15 weeks, about every 16 weeks, or more than about every 16 weeks. In some embodiments, patients are monitored following administration of the anti-IL-23pl9 antibody, anti-IL-23pl9 antibody huml3B8-b, or antigen binding fragment thereof. In some embodiments, the anti-IL-23pl9 antibody, huml3B8-b, or antigen binding fragment thereof is administered at regular intervals throughout the entire treatment regimen.
[0065] In some embodiments of the compositions or methods of the disclosur, the anti-IL-23pl9 antibody, anti-IL-23pl9 antibody huml3B8-b, or antigen binding fragment thereof is administered for about a 2-week treatment period, for about a 4-week treatment period, for about a 6-week treatment period, for about an 8-week treatment period, for about a 12-week treatment period, for about a 24-week treatment period, for about a 36-week treatment period, for about a 48-week treatment period, for about a 52-week treatment period, or for about more than a 52-week treatment period.
[0001] In some embodiments of the compositions or methods of the disclosure, the anti-IL-23pl9 antibody, anti-IL-23pl9 antibody huml3B8-b, or antigen binding fragment thereof is administered as a first dose, a second dose, and / or one or more subsequent or maintenance doses, wherein the first dose, the second dose, and / or the one or more subsequent or maintenance doses are about 100 mg, about 125 mg, about 150 mg, about 175 mg, or aboutPCT / US2026 / 027788 12 May 2026 (12.05.2026)Attorney Ref. No. 0094-0218W01200 mg. In some embodiments, a first dose of about 100 mg is administered to the patient, a second dose of about 100 mg is administered to the patient, and one or more subsequent or maintenance doses of about 100 mg are administered to the patient. In some embodiments, a first dose of about 200 mg is administered to the patient, a second dose of about 200 mg is administered to the patient, and one or more subsequent or maintenance doses of about 200 mg are administered to the patient. In some embodiments, the first, second, and one or more subsequent doses that are administered to the patient are the same. In some embodiments, the first, second, and one or more subsequent doses that are adminterested to the patient are different. In some embodiments, the first and second doses that are administered to the patient are the same and the subsequent doses are variable. In some embodiments, the second and subsequent doses that are administered to the patient are different from the first dose that is administered to the patient.
[0002] In some embodiments, the treatment regimen or administration protocol consists of one or more phases in which a dose of the anti-IL-23pl9 antibody, huml3B8-b, or antigen binding fragment thereof is administered one or more times during each phase. In some embodiments, the anti-IL-23pl9 antibody, huml3B8-b, or antigen binding fragment thereof is not administered during one or more phases. In some embodiments, the protocol consists of a first phase, a second phase, and a subsequent, maintenance, extension, or follow-up phase, wherein a first dose of the anti-IL-23pl9 antibody, huml3B8-b, or antigen binding fragment thereof is administered to the patient in the first phase, a second dose of the anti-IL-23pl9 antibody, huml3B8-b, or antigen binding fragment thereof is administered to the patient in the second phase, and a subsequent dose of the anti-IL-23pl9 antibody, huml3B8-b, or antigen binding fragment thereof is administered to the patient in the subsequent, maintenance, extension, or follow-up phase. The patient may receive the anti-IL-23pl9 antibody, huml3B8-b, or antigen binding fragment thereof in one, more than one, or all three phases of the treatment regimen. In some embodiments, the patient is moved to the next phase (i.e., second phase or subsequent phase) only if specific benchmarks are met in the current phase (i.e., first phase or second phase, respectively).
[0003] As used herein, the term "Week 0" refers to the first day on which the anti-IL-23pl9 antibody, anti-IL-23pl9 antibody huml3B8-b, or antigen binding fragment thereof is administered to the patient. The term Week 0 also refers to the first day the pharmaceutical composition of an anti-IL-23pl9 antibody huml3B8-b or anti-IL-23pl9 antibody huml3B8-b medicament is administered to the patient.PCT / US2026 / 027788 12 May 2026 (12.05.2026)Attorney Ref. No. 0094-0218W01
[0004] In one embodiment, the disclosure provides a method of treating sarcoma in a patient in need thereof, comprising administering a pharmaceutical composition comprising an anti-IL-23pl9 antibody huml3B8-b to a patient, wherein huml3B8-b comprises (i) a light chain polypeptide comprising the amino acid sequence of SEQ ID NO: 1, and (ii) a heavy chain polypeptide comprising the amino acid sequence of SEQ ID NO: 2.
[0005] In some embodiments of the disclosure, the method of treating sarcoma comprises a treatment phase and an extension phase.
[0006] In some embodiments of the disclosure, huml3B8-b is administered to the patient at Week 0, at about Week 4, and about every 4 weeks thereafter during the treatment phase.
[0007] In some embodiments of the disclosure, a therapeutically effective amount of huml3B8-b is administered to the patient during the treatment phase.
[0008] In some embodiments of the disclosure, about 100 mg or about 200 mg of huml3B8-b is administered to the patient during the treatment phase.
[0009] In some embodiments of the disclosure, about 200 mg of huml3B8-b is administered to the patient during the treatment phase.
[0010] In some embodiments of the disclosure, huml3B8-b is administered to the patient subcutaneously during the treatment phase.
[0011] In some embodiments of the disclosure, huml3B8-b is administered to the patient by subcutaneous injection during the treatment phase.
[0012] In some embodiments of the disclosure, huml3B8-b is administered to the patient using an auto-injector or prefilled syringe during the treatment phase.
[0013] In some embodiments of the disclosure, a first dose of huml3B8-b is administered to the patient on Week 0, a second dose of huml3B8-b is administered to the patient at about Week 4, and subsequent doses of huml3B8-b are administered to the patient at about every 4 weeks thereafter during the treatment phase.
[0014] In some embodiments of the disclosure, the first dose of huml3B8-b, the second dose of huml3B8-b, and subsequent doses of huml3B8-b are the same.
[0015] In some embodiments of the disclosure, the first dose of huml3B8-b, the second dose of huml3B8-b, and subsequent doses of huml3B8-b comprise about 100 mg of huml3B8-b.
[0016] In some embodiments of the disclosure, the first dose of huml3B8-b, the second dose of huml3B8-b, and subsequent doses of huml3B8-b comprise about 200 mg of hum!3B8-b.PCT / US2026 / 027788 12 May 2026 (12.05.2026)Attorney Ref. No. 0094-0218W01
[0017] In some embodiments of the disclosure, the first dose of huml3B8-b, the second dose of huml3B8-b, and subsequent doses of huml3B8-b are different.
[0018] In some embodiments of the disclosure, the first dose of huml3B8-b comprises about 100 mg or about 200 mg of huml3B8-b.
[0019] In some embodiments of the disclosure, the second dose of huml3B8-b comprises about 100 mg or about 200 mg of huml3B8-b.
[0020] In some embodiments of the disclosure, the subsequent doses of huml3B8-b comprise about 100 mg or about 200 mg of huml3B8-b.
[0021] In some embodiments of the disclosure, the first dose of huml3B8-b comprises about 100 mg of huml3B8-b, and the amount of huml3B8-b administered in the second dose and subsequent doses is different from the first dose.
[0022] In some embodiments of the disclosure, the first dose of huml3B8-b comprises about 200 mg of huml3B8-b, and the amount of huml3B8-b administered in the second dose and subsequent doses is different from the first dose.
[0023] In some embodiments of the disclosure, huml3B8-b is administered to the patient for at least up to about 12 weeks, for at least up to about 16 weeks, for at least up to about 20 weeks, for at least up to about 24 weeks, for at least up to about 28 weeks, for at least up to about 32 weeks, for at least up to about 36 weeks, for at least up to about 40 weeks, for at least up to about 44 weeks, for at least up to about 48 weeks, for at least up to about 52 weeks, or for more than at least up to about 52 weeks during the treatment phase.
[0024] In some embodiments of the compositions or methods of the disclosure, the anti-IL-23pl9 antibody, anti-IL-23pl9 antibody huml3B8-b, or antigen binding fragment thereof is used for the treatment of sarcoma in a patient in need thereof, wherein the patient has stable disease (SD) following treatment. As used herein, the term "stable disease" can mean that a patient's tumor is not shrinking significantly (e.g., less than 30% reduction) and is not growing significantly (e.g., less than 20% increase). Stable disease can also mean that no new tumors are appearing in the patient. Although stable disease may not be a complete response, it can be an indication that the treatment may be controlling cancer growth in the patient.
[0025] In some embodiments of the compositions or methods of the disclosure, the anti-IL-23pl9 antibody, anti-IL-23pl9 antibody huml3B8-b, or antigen binding fragment thereof is used for the treatment of sarcoma in a patient in need thereof, wherein treatment results in expression of one or more oncogenic transcription factors is downrelugated in the patient, one or more immune regulators is modulated in the patient, and / or population shifts in one orPCT / US2026 / 027788 12 May 2026 (12.05.2026)Attorney Ref. No. 0094-0218W01more of T cells, monocytes, and / or NK cells in the patient. In some embodiments, the one or more oncogenic transcription factors is FOS, EGR1, and / or STAT3. In some embodiemnts, the one or more immune regulators is ICOSLG.
[0026] In some embodiments of the compositions or methods of the disclosure, the anti-IL-23pl9 antibody, anti-IL-23pl9 antibody huml3B8-b, or antigen binding fragment thereof is used for the treatment of sarcoma in a patient in need thereof, wherein the patient has a time-to-progression ratio of at least 1.3 following treatment. As used herein, the term "time-to-progression ratio" or "TTPr" is an assessment of the efficacy of a targeted or immune therapy that compares the time to progression (TTP) of two consecutive treatment lines within the same patient. A higher TTPr, particularly exceeding a standard threshold of 1.3, may suggest that a treatment is delaying progression compared to prior treatment.
[0027] In some embodiments of the compositions or methods of the disclosure, the anti-IL-23pl9 antibody, anti-IL-23pl9 antibody huml3B8-b, or antigen binding fragment thereof is used for the treatment of sarcoma in a patient in need thereof, wherein the patient has an at least 25% reduction in Maximum Standardized Uptake Value (SUVmax) on fluorodeoxyglucose Positron Emission Tomography (FDG-PET) following treatment. As used herein, SUVmax on an FDG-PET scan is a measure of how much of the radioactive tracer fluorodeoxyglucose is taken up by a specific area in the body, particularly a tumor or lesion, and is used to assess tumor activity, stage cancer, and evaluate treatment response. Higher SUVmax values generally indicate greater metabolic activity, which can be associated with a higher likelihood of malignancy.
[0028] In some embodiments of the compositions or methods of the disclosure, the anti-IL-23pl9 antibody, anti-IL-23pl9 antibody huml3B8-b, or antigen binding fragment thereof is used for the treatment of sarcoma in a patient in need thereof, wherein treatment results in progression-free survival (PFS) of between 1.7 and 3.3 months. As used herein, PFS is a measure of how long a patient's cancer remains stable or does not progress, after starting a treatment. PFS is calculated from the start of treatment to the time the cancer progresses or the patient dies. PFS is a common endpoint used to evaluate the effectiveness of a cancer treatment.
[0029] In some embodiments of the compositions or methods of the disclosure, the anti-IL-23pl9 antibody, anti-IL-23pl9 antibody huml3B8-b, or antigen binding fragment thereof is used for the treatment of sarcoma in a patient in need thereof, wherein treatment results in overall survival (OS) of between 9.7 and 15.0 months. As used herein, OS refers to the length of time a patient lives after a diagnosis or treatment begins, and is a metric forPCT / US2026 / 027788 12 May 2026 (12.05.2026)Attorney Ref. No. 0094-0218W01evaluating the effectiveness of cancer treatment. OS is measured from the start of treatment to the time of death, regardless of the cause of death.
[0030] As used herein, the term "significant improvement" refers to significant positive effect in a response in patients taking an anti-IL-23pl9 antibody, anti-IL-23pl9 antibody huml3B8-b, or antigen binding fragment thereof, relative to patients taking a placebo. In some embodiments, the significant improvement refers to a statistically significant improvement.
[0031] The term "statistically significant," as used herein, means having a probability of less than 10% under the relevant null hypothesis (i.e., p<0.1). In some embodiments, a p-value less than 0.05 is considered to be statistically significant. In some embodiments, a p-value less than 0.01 is considered to be statistically significant. In some embodiments, a p-value less than 0.005 is considered to be statistically significant. In some embodiments, a p-value less than 0.0025 is considered to be statistically significant. In some embodiments, a p-value less than 0.001 is considered to be statistically significant. In some embodiments, statistical tests will be 2-sided at the 5% significance level, and point estimates are accompanied with 2-sided 95% confidence intervals (Cis), where applicable.
[0032] As used herein, the term "minimal" refers to the number of at risk patients affected by an adverse side effect as a percentage of the to the total number of patients at risk for the adverse side effect. Similarly, when used in reference to other side effects, the term "minimal" refers to the number of at risk patients affected by an other side effect as a percentage of the to the total number of patients at risk for the other side effect.
[0033] The term "Adverse Event (AE)," as used herein, is defined as any untoward medical occurrence in a subject, or clinical investigation subject administered a pharmaceutical product, and which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigation) product, whether or not related to the medicinal (investigational) product.
[0034] In some embodiments of the compositions or methods of the disclosure, the use of an anti-IL-23pl9 antibody, the anti-IL-23pl9 antibody huml3B8-b, or antigen binding fragment thereof results in the patient experiencing minimal or no serious adverse events (SAEs) in the patient.
[0035] In some embodiments of the compositions or methods of the disclosure, the use of an anti-IL-23pl9 antibody, the anti-IL-23pl9 antibody hum!3B8-b, or antigen bindingPCT / US2026 / 027788 12 May 2026 (12.05.2026)Attorney Ref. No. 0094-0218W01fragment thereof results in the patient experiencing minimal or no treatment emergent adverse events (TEAEs) in the patient.
[0036] In some embodiments of the compositions or methods of the disclosure, the use of an anti-IL-23pl9 antibody, the anti-IL-23pl9 antibody huml3B8-b, or antigen binding fragment thereof results in the patient experiencing no increase in treatment emergent adverse events (TEAEs) or severe adverse events (SAEs) for at least up to about 12 weeks, for at least up to about 16 weeks, for at least up to about 20 weeks, for at least up to about 24 weeks, for at least up to about 28 weeks, for at least up to about 32 weeks, for at least up to about 36 weeks, for at least up to about 40 weeks, for at least up to about 44 weeks, for at least up to about 48 weeks, for at least up to about 52 weeks, or for more than at least up to about 52 weeks.Embodiments
[0037] Embodiment 1 : A method of treating sarcoma in a patient in need thereof, comprising administering a pharmaceutical composition to the patient, wherein the pharmaceutical composition comprises an anti-IL-23pl9 antibody or antigen binding fragment thereof.
[0038] Embodiment 2: The method of embodiment 1, wherein the sarcoma is advanced osteosarcoma or soft tissue sarcoma.
[0039] Embodiment 3 : The method of either embodiment 1 or embodiment 2, wherein the anti-IL-23pl9 antibody or antigen binding fragment thereof is the anti-IL-23pl9 antibody huml3B8-b.
[0040] Embodiment 4: The method of embodiment 3, wherein huml3B8-b comprises:(a) a light chain polypeptide comprising the amino acid sequence of SEQ ID NO: 1, and(b) a heavy chain polypeptide comprising the amino acid sequence of SEQ ID NO: 2.
[0041] Embodiment 5: The method of any one of embodiments 1 to 4, wherein a therapeutically effective amount of the pharmaceutical composition is administered to the patient.
[0042] Embodiment 6: The method of any one of embodiments 1 to 5, wherein a first dose of the pharmaceutical composition is administered to the patient at Week 0.
[0043] Embodiment 7: The method of embodiment 6, wherein the first dose of the pharmaceutical composition comprises about 100 mg or about 200 mg of the anti-IL-23pl9PCT / US2026 / 027788 12 May 2026 (12.05.2026)Attorney Ref. No. 0094-0218W01antibody or antigen binding fragment thereof, and wherein the anti-IL-23pl9 antibody or antigen binding fragment thereof is optionally the anti-IL-23pl9 antibody huml3B8-b.
[0044] Embodiment 8: The method of either embodiment 6 or embodiment 7, wherein a second dose of the pharmaceutical composition is administered to the patient after the first dose of the pharmaceutical composition is administered to the patient.
[0045] Embodiment 9: The method of embodiment 8, wherein the second dose of the pharmaceutical composition comprises about 100 mg or about 200 mg of the anti-IL-23pl9 antibody or antigen binding fragment thereof, and wherein the anti-IL-23pl9 antibody or antigen binding fragment thereof is optionally the anti-IL-23pl9 antibody huml3B8-b.
[0046] Embodiment 10: The method of embodiment 8, wherein the second dose of the pharmaceutical composition is administered to the patient about 4 weeks after the first dose of the pharmaceutical composition is administered to the patient.
[0047] Embodiment 11 : The method of any one of embodiments 8 to 10, wherein one or more subsequent doses of the pharmaceutical composition are administered to the patient after the second dose of the pharmaceutical composition is administered to the patient.
[0048] Embodiment 12: The method of embodiment 11, wherein the one or more subsequent doses of the pharmaceutical composition comprise about 100 mg or about 200 mg of the anti-IL-23pl9 antibody or antigen binding fragment thereof, and wherein the anti-IL-23pl9 antibody or antigen binding fragment thereof is optionally the anti-IL-23pl9 antibody huml3B8-b.
[0049] Embodiment 13: The method of either embodiment 11 or embodiment 12, wherein the one or more subsequent doses of the pharmaceutical composition are administered to the patient about every 4 weeks after the previous dose of the pharmaceutical composition is administered to the patient.
[0050] Embodiment 14: The method according to any one of embodiments 11 to 13, wherein the pharmaceutical composition is administered to the patient for at least up to about 12 weeks, for at least up to about 16 weeks, for at least up to about 20 weeks, for at least up to about 24 weeks, for at least up to about 28 weeks, for at least up to about 32 weeks, for at least up to about 36 weeks, for at least up to about 40 weeks, for at least up to about 44 weeks, for at least up to about 48 weeks, for at least up to about 52 weeks, or for more than at least up to about 52 weeks.
[0051] Embodiment 15: The method of any one of embodiments 1 to 14, wherein the pharmaceutical composition is a stable solution formulation.PCT / US2026 / 027788 12 May 2026 (12.05.2026)Attorney Ref. No. 0094-0218W01
[0052] Embodiment 16: The method of embodiment 15, wherein the stable solution formulation comprises a buffer containing L-histidine and L-histidine hydrochloride, pH 6.0±0.3, polysorbate 80, and sucrose to render the solution isotonic.
[0053] Embodiment 17: The method of embodiment 16, wherein the stable solution formulation comprises 0.05% (w / v) polysorbate 80 and 7% (w / v) sucrose.
[0054] Embodiment 18: The method of any one of embodiments 1 to 17, wherein the pharmaceutical composition is administered to the patient subcutaneously.
[0055] Embodiment 19: The method of embodiment 18, wherein the pharmaceutical composition is administered to the patient by subcutaneous injection.
[0056] Embodiment 20: The method of any one of embodiments 1 to 19, wherein the pharmaceutical composition is administered to the patient using a prefilled syringe or autoinjector device, intravenous (IV) bag, prefilled ampule, single dose vial, or wearable device.
[0057] Embodiment 21 : The method of any one of embodiments 1 to 20, wherein the patient has stable disease following treatment.
[0058] Embodiment 22: The method of any one of embodiments 1 to 20, wherein treatment results in expression of one or more oncogenic transcription factors is downrelugated in the patient, one or more immune regulators is modulated in the patient, and / or population shifts in one or more of T cells, monocytes, and / or NK cells in the patient.
[0059] Embodiment 23 : The method of embodiment 22, wherein the one or more oncogenic transcription factors is FOS, EGR1, and / or STAT3.
[0060] Embodiment 24: The method of embodiment 22, wherein the one or more immune regulators is ICOSLG.
[0061] Embodiment 25: The method of any one of embodiments 1 to 20, wherein the patient has a time-to-progression ratio (TTPr) of at least 1.3 following treatment.
[0062] Embodiment 26: The method of any one of embodiments 1 to 20, wherein the patient has an at least 25% reduction in Maximum Standardized Uptake Value (SUVmax) on fluorodeoxyglucose Positron Emission Tomography (FDG-PET) following treatment.
[0063] Embodiment 27: The method of any one of embodiments 1 to 20, wherein treatment results in progression-free survival (PFS) of between 1.7 and 3.3 months.
[0064] Embodiment 28: The method of any one of embodiments 1 to 20, wherein treatment results in overall survival (OS) of between 9.7 and 15.0 months.
[0065] Embodiment 29: The method of any one of embodiments 1 to 28, wherein administration of the pharmaceutical composition is associated with minimal or no serious adverse events (SAEs) in the patient.PCT / US2026 / 027788 12 May 2026 (12.05.2026)Attorney Ref. No. 0094-0218W01
[0066] Embodiment 30: The method of any one of embodiments 1 to 28, wherein administration of the pharmaceutical composition is associated with minimal or no treatment emergent adverse events (TEAEs) in the patient.
[0067] Embodiment 31 : The method of any one of embodiments 1 to 28, wherein administration of the pharmaceutical composition results in the patient experiencing no increase in treatment emergent adverse events (TEAEs) or severe adverse events (SAEs) for at least up to about 12 weeks, for at least up to about 16 weeks, for at least up to about 20 weeks, for at least up to about 24 weeks, for at least up to about 28 weeks, for at least up to about 32 weeks, for at least up to about 36 weeks, for at least up to about 40 weeks, for at least up to about 44 weeks, for at least up to about 48 weeks, for at least up to about 52 weeks, or for more than at least up to about 52 weeks.
[0068] Embodiment 32: A pharmaceutical composition comprising an anti-IL-23pl9 antibody or antigen binding fragment thereof for use in treating sarcoma in a patient in need thereof.
[0069] Embodiment 33: The pharmaceutical composition of embodiment 32, wherein the sarcoma is advanced osteosarcoma or soft tissue sarcoma.
[0070] Embodiment 34: The pharmaceutical composition of either embodiment 32 or embodiment 33, wherein the anti-IL-23pl9 antibody or antigen binding fragment thereof is the anti-IL-23pl9 antibody huml3B8-b.
[0071] Embodiment 35: The pharmaceutical composition of embodiment 34, wherein huml3B8-b comprises:(a) a light chain polypeptide comprising the amino acid sequence of SEQ ID NO: 1, and(b) a heavy chain polypeptide comprising the amino acid sequence of SEQ ID NO: 2.
[0072] Embodiment 36: The pharmaceutical composition of any one of embodiments 32 to 35, wherein a therapeutically effective amount of the pharmaceutical composition is administered to the patient.
[0073] Embodiment 37: The pharmaceutical composition of any one of embodiments 32 to 36, wherein a first dose of the pharmaceutical composition is administered to the patient at Week 0.
[0074] Embodiment 38: The pharmaceutical composition of embodiment 37, wherein the first dose of the pharmaceutical composition comprises about 100 mg or about 200 mg of the anti-IL-23pl9 antibody or antigen binding fragment thereof, and wherein the anti-IL-23pl9PCT / US2026 / 027788 12 May 2026 (12.05.2026)Attorney Ref. No. 0094-0218W01antibody or antigen binding fragment thereof is optionally the anti-IL-23pl9 antibody huml3B8-b.
[0075] Embodiment 39: The pharmaceutical composition of either embodiment 37 or embodiment 38, wherein a second dose of the pharmaceutical composition is administered to the patient after the first dose of the pharmaceutical composition is administered to the patient.
[0076] Embodiment 40: The pharmaceutical composition of embodiment 39, wherein the second dose of the pharmaceutical composition comprises about 100 mg or about 200 mg of the anti-IL-23pl9 antibody or antigen binding fragment thereof, and wherein the anti-IL-23pl9 antibody or antigen binding fragment thereof is optionally the anti-IL-23pl9 antibody huml3B8-b.
[0077] Embodiment 41 : The pharmaceutical composition of embodiment 39, wherein the second dose of the pharmaceutical composition is administered to the patient about 4 weeks after the first dose of the pharmaceutical composition is administered to the patient.
[0078] Embodiment 42: The pharmaceutical composition of any one of embodiments 39 to 41, wherein one or more subsequent doses of the pharmaceutical composition are administered to the patient after the second dose of the pharmaceutical composition is administered to the patient.
[0079] Embodiment 43 : The pharmaceutical composition of embodiment 42, wherein the one or more subsequent doses of the pharmaceutical composition comprise about 100 mg or about 200 mg of the anti-IL-23pl9 antibody or antigen binding fragment thereof, and wherein the anti-IL-23pl9 antibody or antigen binding fragment thereof is optionally the anti-IL-23pl9 antibody huml3B8-b.
[0080] Embodiment 44: The pharmaceutical composition of either embodiment 42 or embodiment 43, wherein the one or more subsequent doses of the pharmaceutical composition are administered to the patient about every 4 weeks after the previous dose of the pharmaceutical composition is administered to the patient.
[0081] Embodiment 45: The pharmaceutical composition according to any one of embodiments 42 to 44, wherein the pharmaceutical composition is administered to the patient for at least up to about 12 weeks, for at least up to about 16 weeks, for at least up to about 20 weeks, for at least up to about 24 weeks, for at least up to about 28 weeks, for at least up to about 32 weeks, for at least up to about 36 weeks, for at least up to about 40 weeks, for at least up to about 44 weeks, for at least up to about 48 weeks, for at least up to about 52 weeks, or for more than at least up to about 52 weeks.PCT / US2026 / 027788 12 May 2026 (12.05.2026)Attorney Ref. No. 0094-0218W01
[0082] Embodiment 46: The pharmaceutical composition of any one of embodiments 32 to 45, wherein the pharmaceutical composition is a stable solution formulation.
[0083] Embodiment 47: The pharmaceutical composition of embodiment 46, wherein the stable solution formulation comprises a buffer containing L-histidine and L-histidine hydrochloride, pH 6.0±0.3, polysorbate 80, and sucrose to render the solution isotonic.
[0084] Embodiment 48: The pharmaceutical composition of embodiment 47, wherein the stable solution formulation comprises 0.05% (w / v) polysorbate 80 and 7% (w / v) sucrose.
[0085] Embodiment 49: The pharmaceutical composition of any one of embodiments 32 to 48, wherein the pharmaceutical composition is administered to the patient subcutaneously.
[0086] Embodiment 50: The pharmaceutical composition of embodiment 49, wherein the pharmaceutical composition is administered to the patient by subcutaneous injection.
[0087] Embodiment 51: The pharmaceutical composition of any one of embodiments 32 to 50, wherein the pharmaceutical composition is administered to the patient using a prefilled syringe or auto-injector device, intravenous (IV) bag, prefilled ampule, single dose vial, or wearable device.
[0088] Embodiment 52: The pharmaceutical composition of any one of embodiments 32 to 51, wherein the patient has stable disease following treatment.
[0089] Embodiment 53: The pharmaceutical composition of any one of embodiments 32 to 51, wherein treatment results in expression of one or more oncogenic transcription factors is downrelugated in the patient, one or more immune regulators is modulated in the patient, and / or population shifts in one or more of T cells, monocytes, and / or NK cells in the patient.
[0090] Embodiment 54: The pharmaceutical composition of embodiment 53, wherein the one or more oncogenic transcription factors is FOS, EGR1, and / or STAT3.
[0091] Embodiment 55: The pharmaceutical composition of embodiment 53, wherein the one or more immune regulators is ICOSLG.
[0092] Embodiment 56: The pharmaceutical composition of any one of embodiments 32 to 51, wherein the patient has a time-to-progression ratio (TTPr) of at least 1.3 following treatment.
[0093] Embodiment 57: The pharmaceutical composition of any one of embodiments 32 to 51, wherein the patient has an at least 25% reduction in Maximum Standardized Uptake Value (SUVmax) on fluorodeoxyglucose Positron Emission Tomography (FDG-PET) following treatment.PCT / US2026 / 027788 12 May 2026 (12.05.2026)Attorney Ref. No. 0094-0218W01
[0094] Embodiment 58: The pharmaceutical composition of any one of embodiments 32 to 51, wherein treatment results in progression-free survival (PFS) of between 1.7 and 3.3 months.
[0095] Embodiment 59: The pharmaceutical composition of any one of embodiments 32 to 51, wherein treatment results in overall survival (OS) of between 9.7 and 15.0 months.
[0096] Embodiment 60: The pharmaceutical composition of any one of embodiments 32 to 59, wherein administration of the pharmaceutical composition is associated with minimal or no serious adverse events (SAEs) in the patient.
[0097] Embodiment 61 : The pharmaceutical composition of any one of embodiments 32 to 59, wherein administration of the pharmaceutical composition is associated with minimal or no treatment emergent adverse events (TEAEs) in the patient.
[0098] Embodiment 62: The pharmaceutical composition of any one of embodiments 32 to 59, wherein administration of the pharmaceutical composition results in the patient experiencing no increase in treatment emergent adverse events (TEAEs) or severe adverse events (SAEs) for at least up to about 12 weeks, for at least up to about 16 weeks, for at least up to about 20 weeks, for at least up to about 24 weeks, for at least up to about 28 weeks, for at least up to about 32 weeks, for at least up to about 36 weeks, for at least up to about 40 weeks, for at least up to about 44 weeks, for at least up to about 48 weeks, for at least up to about 52 weeks, or for more than at least up to about 52 weeks.
[0099] Embodiment 63 : The use of an anti-IL-23pl9 antibody or antigen binding fragment thereof for the manufacture of a medicament for the treatment of sarcoma in a patient in need thereof.
[0100] Embodiment 64: The use of embodiment 63, wherein the sarcoma is advanced osteosarcoma or soft tissue sarcoma.
[0101] Embodiment 65: The use of either embodiment 63 or embodiment 64, wherein the anti-IL-23pl9 antibody or antigen binding fragment thereof is the anti-IL-23pl9 antibody huml3B8-b.
[0102] Embodiment 66: The use of embodiment 65, wherein huml3B8-b comprises:(a) a light chain polypeptide comprising the amino acid sequence of SEQ ID NO: 1, and(b) a heavy chain polypeptide comprising the amino acid sequence of SEQ ID NO: 2.
[0103] Embodiment 67: The use of any one of embodiments 63 to 66, wherein a therapeutically effective amount of the medicament is administered to the patient.PCT / US2026 / 027788 12 May 2026 (12.05.2026)Attorney Ref. No. 0094-0218W01
[0104] Embodiment 68: The use of any one of embodiments 63 to 67, wherein a first dose of the medicament is administered to the patient at Week 0.
[0105] Embodiment 69: The use of embodiment 68, wherein the first dose of the medicament comprises about 100 mg or about 200 mg of the anti-IL-23pl9 antibody or antigen binding fragment thereof, and wherein the anti-IL-23pl9 antibody or antigen binding fragment thereof is optionally the anti-IL-23pl9 antibody huml3B8-b.
[0106] Embodiment 70: The use of either embodiment 68 or embodiment 69, wherein a second dose of the medicament is administered to the patient after the first dose of the medicament is administered to the patient.
[0107] Embodiment 71 : The use of embodiment 70, wherein the second dose of the medicament comprises about 100 mg or about 200 mg of the anti-IL-23pl9 antibody or antigen binding fragment thereof, and wherein the anti-IL-23pl9 antibody or antigen binding fragment thereof is optionally the anti-IL-23pl9 antibody huml3B8-b.
[0108] Embodiment 72: The use of embodiment 70, wherein the second dose of the medicament is administered to the patient about 4 weeks after the first dose of the medicament is administered to the patient.
[0109] Embodiment 73: The use of any one of embodiments 70 to 72, wherein one or more subsequent doses of the medicament are administered to the patient after the second dose of the medicament is administered to the patient.
[0110] Embodiment 74: The use of embodiment 73, wherein the one or more subsequent doses of the medicament comprise about 100 mg or about 200 mg of the anti-IL-23pl9 antibody or antigen binding fragment thereof, and wherein the anti-IL-23pl9 antibody or antigen binding fragment thereof is optionally the anti-IL-23pl9 antibody huml3B8-b.[oni] Embodiment 75: The use of either embodiment 73 or embodiment 74, wherein the one or more subsequent doses of the medicament are administered to the patient about every 4 weeks after the previous dose of the medicament is administered to the patient.
[0112] Embodiment 76: The use according to any one of embodiments 73 to 75, wherein the medicament is administered to the patient for at least up to about 12 weeks, for at least up to about 16 weeks, for at least up to about 20 weeks, for at least up to about 24 weeks, for at least up to about 28 weeks, for at least up to about 32 weeks, for at least up to about 36 weeks, for at least up to about 40 weeks, for at least up to about 44 weeks, for at least up to about 48 weeks, for at least up to about 52 weeks, or for more than at least up to about 52 weeks.PCT / US2026 / 027788 12 May 2026 (12.05.2026)Attorney Ref. No. 0094-0218W01
[0113] Embodiment 77: The use of any one of embodiments 63 to 76, wherein the medicament is a stable solution formulation.
[0114] Embodiment 78: The use of embodiment 77, wherein the stable solution formulation comprises a buffer containing L-histidine and L-histidine hydrochloride, pH 6.0±0.3, polysorbate 80, and sucrose to render the solution isotonic.
[0115] Embodiment 79: The use of embodiment 78, wherein the stable solution formulation comprises 0.05% (w / v) polysorbate 80 and 7% (w / v) sucrose.
[0116] Embodiment 80: The use of any one of embodiments 63 to 79, wherein the medicament is administered to the patient subcutaneously.
[0117] Embodiment 81 : The use of embodiment 80, wherein the medicament is administered to the patient by subcutaneous injection.
[0118] Embodiment 82: The use of any one of embodiments 63 to 81, wherein the medicament is administered to the patient using a prefilled syringe or auto-injector device, intravenous (IV) bag, prefilled ampule, single dose vial, or wearable device.
[0119] Embodiment 83 : The use of any one of embodiments 63 to 82, wherein the patient has stable disease following treatment.
[0120] Embodiment 84: The use of any one of embodiments 63 to 82, wherein treatment results in expression of one or more oncogenic transcription factors is downrelugated in the patient, one or more immune regulators is modulated in the patient, and / or population shifts in one or more of T cells, monocytes, and / or NK cells in the patient.
[0121] Embodiment 85: The use of embodiment 84, wherein the one or more oncogenic transcription factors is FOS, EGR1, and / or STAT3.
[0122] Embodiment 86: The use of embodiment 84, wherein the one or more immune regulators is ICOSLG.
[0123] Embodiment 87: The use of any one of embodiments 63 to 82, wherein the patient has a time-to-progression ratio (TTPr) of at least 1.3 following treatment.
[0124] Embodiment 88: The use of any one of embodiments 63 to 82, wherein the patient has an at least 25% reduction in Maximum Standardized Uptake Value (SUVmax) on fluorodeoxyglucose Positron Emission Tomography (FDG-PET) following treatment.
[0125] Embodiment 89: The use of any one of embodiments 63 to 82, wherein treatment results in progression-free survival (PFS) of between 1.7 and 3.3 months.
[0126] Embodiment 90: The use of any one of embodiments 63 to 82, wherein treatment results in overall survival (OS) of between 9.7 and 15.0 months.PCT / US2026 / 027788 12 May 2026 (12.05.2026)Attorney Ref. No. 0094-0218W01
[0127] Embodiment 91 : The use of any one of embodiments 63 to 90, wherein administration of the medicament is associated with minimal or no serious adverse events (SAEs) in the patient.
[0128] Embodiment 92: The use of any one of embodiments 63 to 90, wherein administration of the medicament is associated with minimal or no treatment emergent adverse events (TEAEs) in the patient.
[0129] Embodiment 93 : The use of any one of embodiments 63 to 90, wherein administration of the medicament results in the patient experiencing no increase in treatment emergent adverse events (TEAEs) or severe adverse events (SAEs) for at least up to about 12 weeks, for at least up to about 16 weeks, for at least up to about 20 weeks, for at least up to about 24 weeks, for at least up to about 28 weeks, for at least up to about 32 weeks, for at least up to about 36 weeks, for at least up to about 40 weeks, for at least up to about 44 weeks, for at least up to about 48 weeks, for at least up to about 52 weeks, or for more than at least up to about 52 weeks.EXAMPLES
[0130] The Examples that follow are illustrative of specific embodiments of the disclosure, and various uses thereof. They are set forth for explanatory purposes only and should not be construed as limiting the scope of the disclosure in any way.Example 1. Analysis of efficacy and safety of tildrakizumab 200 mg in advanced osteosarcomas and soft tissue sarcomas.
[0131] High expression of IL-23 relative to normal adj acent tissue has been reported in many human cancer types and is associated with increased tumour incidence and growth (Langowski et al., 2006; Langowski et al., 2007). Researchers at the Garvan Institute of Medical Research, including the inventors, have demonstrated an oncogenic role for IL-23 in osteosarcoma (Jones, 2019; Kansara etal., 2017), and in soft tissue sarcoma (fibrosarcoma) (Kansara et al., 2014). Briefly, these researchers found that mice deficient in IL-23 were protected from the development of osteosarcoma and fibrosarcoma compared to wildtype animals in a radiation model of osteosarcoma. In that study, 80% of mice were tumour free at 2 years compared to all wildtype mice succumbing to tumours (HR 9.4, 95%CI 3.3-27;<0.0001) (Figures 2A-2B). Within a methylcholanthrene (MCA) carcinogen model of fibrosarcoma, IL-23 deficient mice were significantly resistant to tumour formation and thePCT / US2026 / 027788 12 May 2026 (12.05.2026)Attorney Ref. No. 0094-0218W01few tumours that arose were significantly delayed (P=0.0009 Fisher test). In human osteosarcoma, more than 60% of samples demonstrated focal staining for IL23A (pl 9) expression (12% high, 24% medium), while little staining was observed in normal human bone (NHB) (Figure 2D). In an independent cohort with associated survival data, more than 70% of samples exhibited significantly increased expression of IL-23 over NHB (qRT-PCR), with 53% having >2 -fold increase and with 34% have >5-fold greater expression. High IL23 expression (>8-fold) was associated with worse survival (Figure 2F; HR 0.33, 95%CI 0.06-1.69, =0.0427) (Figure 2C) (Kansara et al., 2014). Treatment with IL-23 blocking antibody (aIL23) slows the growth of established osteosarcomas (P=0.042*1 (Figure 2G) and this correlates with longer survival (P=0.032 Mantel-Cox). Blocking IL-23 increased markers of cytotoxic T-cell activity, CD8+ and NKT in the tumor microenvironment (TME).
[0132] In addition to preclinical sarcoma research, IL-23 has shown a driver oncogenic role in castrate resistant prostate cancer (Tawbi eta\., 2017). High expression of IL-23 in mammary cancer has also been shown to be associated with increased myeloid cells and neutrophils and reduced CD4+ and CD8+ T-cells in the tumor microenvironment (TME) (Langowski et al., 2007). IL-23 was found to increase liver cancer metastasis (Langowski et al., 2006) and high IL-23 expression was associated with poor survival in patients with clear cell renal carcinoma (Jones, 2019). Prophylactic blocking of IL-23 has been shown to significantly suppress experimental lung metastases of Bl 6F 10 melanoma, RM-1 prostate carcinoma, and 3LL lung carcinoma (Kansara et al., 2019; Nie et al., 2017; Li et al., 2012).
[0133] The results described above support a further signal-seeking study of anti-IL-23 therapy both as an anti-tumour agent and / or as a priming therapy prior to an ICB (Immune Checkpoint Blockade).
[0134] A substudy analysis was conducted to assess the clinincal activity of tildrakizumab in patients with advanced osteosarcomas or soft tissue sarcomas as measured by objective tumor response (RECIST vl.l) or the ratio of time-to-progression on study over the preceding period. Tildrakizumab was found to be safe and well tolerated.1. Rationale of the Study and Objectives
[0135] The substudy analysis was proposed to examine the clinical activity of tildrakizumab for treating metastatic osteosarcoma or soft tissue sarcoma in patients for which no further systemic therapies are available. Additionally, the assessment of potential efficacy of single-agent tildrakizumab in the treatment of malignancies and correlativePCT / US2026 / 027788 12 May 2026 (12.05.2026)Attorney Ref. No. 0094-0218W01studies will allow for the characterization of the tumor immune environment and determinants in response to immunotherapy in IL-23 expression tumors.Objectives
[0136] The primary objective was to test the clinical activity of tildrakizumab as measured by objective tumor response (RECIST vl .1) or the ratio of time-to-progression on study over the preceding period.
[0137] Secondary Objectives were to determine: 1) the overall survival (OS) (death from any cause); 2) overall survival in 12 months; 3) progression free survival; 4) progression free survival at 6 months; 5) safety and tolerability of treatment (rates of adverse events); and 6) health related quality of life during treatment.
[0138] Additionally, tertiary and correlative objectives were considered in the sarcoma study. Those objectives included:1. The evaluation of biomarkers that may correlate with clinical activity, including response, resistance, and tolerability, including evidence for immune reactions in tumor biopsies;2. The evaluation of the pre-treatment tumor microenvironment as compared with the post-treatment microenvironment; and3. The evaluation of the clinical activity of tildrakizumab as measured by positron emission tomography (PET) response.2. Materials and MethodsStudy design, patients, and treatment plans
[0139] A single arm, open label, multi-center phase II signal-seeking trial for patients with pathologically confirmed, treatment-refractory advanced osteosarcoma and other sarcomas with molecular profiling was performed. The study consisted of two groups with sixteen patients each: 1) advanced osteosarcoma, and 2) other advanced soft tissue sarcomas.Patients met all inclusion criteria (see Table 1) and none of the exclusion criteria (see Table 2) to be eligible for the substudy.Table 1: Inclusion Criteria1. Adults, aged 18 years and older, with pathologically confirmed advanced osteosarcoma or soft-tissue sarcoma;PCT / US2026 / 027788 12 May 2026 (12.05.2026)Attorney Ref. No. 0094-0218W012. Has measurable disease as defined by RECIST 1.1;3. Confirmation of molecular eligibility by the molecular tumor board;4. ECOG 0-2;5. Sufficient and accessible tumor tissue for exploratory objectives;6. Received and failed all standard anticancer therapy or have documented unsuitability for any further standard therapy, if standard therapy exists;7. Clinical or radiological progression on or following last anticancer therapy unless such anticancer therapy stopped due to toxicity / treatment intolerance;8. Adequate organ system function as assessed by the following minimal laboratory requirements (within 7 days prior to first administration of study drug):a) bone marrow function; platelets >100 x 109 / L, ANC > 1.5 x 109 / L, and hemoglobin > 9 g / dL (5.6 mmol / L);b) liver function; ALT / AST < 3 x ULN (in the absence of liver metastases, < 5 x ULN for patients with liver involvement) and total bilirubin < 1.5 x ULN; and c) renal function; serum creatinine < 1.5 x ULN.9. Archival tissue sample available;10. Willing and able to comply with all study requirements, including treatment, timing, and on-treatment biopsy;11. Signed, written informed consent to participation in the specific treatment substudy; 12. Patients were considered to be eligible according to the following tuberculosis (TB) screening criteria, defined as:a) no history of untreated latent or active TB prior to screening;b) has no signs or symptoms suggestive of active TB upon medical history and / or physical examination;c) has had no recent close contact with a person with active TB or if there has been such contact, to be referred to a respiratory phsyican at least 4 weeks prior to first administration of study medicantion;d) has a negative diagnostic TB test result, defined as a negative intradermal tuberculin skin test (TST) or a negative QuantiFERON-TB Gold Test (QFTG) within 4 weeks prior to first administration of study medication;e) subjects who have a positive contact history, or a positive TST or QFTG test, or have signs or symptoms suggestive of active TB upon medical history and physicalPCT / US2026 / 027788 12 May 2026 (12.05.2026)Attorney Ref. No. 0094-0218W01examination, must have a negative X-ray (both posterior-anterior and lateral views) or chest computed tomography (CT) scan taken within 4 weeks prior to first administration of study medication to exclude current active TB or old inactive TB, read by a qualified radiologist;f) patients with LTBI, defined as a positive TST and QFTG but no clinical and radiological evidence of active TB infection, may be included if they receive prophylactic treatment, or have previously completed an adequate course of prophylactic treatment according to local guidelines or regulations without subsequent new exposure to active TB; prophylactic treatment for LTBI must be initiated at least 4 weeks prior to first administration of study medication, as per local guidelines;g) referral to a respiratory specialist physician is strongly encouraged to assess the need for repeat of prophylactic therapy if there is a history of new exposure to active TB subsequent to completion of prior treatment for LTBI or if prior treatment of LTBI was completed more than 3 months prior to screening.13. Female subjects must be:a) Postmenopausal status as determined by:i) >45 years of age with >1 year since last menses >= 2 years after completion of last dose cytotoxic chemotherapy; orii) pre-m enopausal female and agrees to abstain from heterosexual activity; or use a medically accepted and appropriate effective method of contraception. 14. Patient must have negative human immunodeficiency virus (HIV) test result, hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV) test results.15. For women of childbearing potential, a negative serum pregnancy test at screening and a negative urine pregnancy test within 24 hours prior to the first dose of study medication.16. Patient must have a satisfactory physical examination within normal limits or clinically acceptable limits to the investigator prior to the first dose of study medication.Table 2. Exclusion Criteria1. Contraindications to investigational product;2. Known history of hypersensitivity to active or inactive components of investigational product or latex;PCT / US2026 / 027788 12 May 2026 (12.05.2026)Attorney Ref. No. 0094-0218W013. Previous treatment with tildrakizumab (MK-3222) or other IL-23 / Th-17 pathway inhibitors, including p40, pl 9, and IL- 17 antagonists;4. Specific co-morbidities or conditions (e.g., psychiatric) or concomitant medications which may interact with the investigational product;5. Presence of any infection or history of recurrent infection requiring treatment with systemic antibiotics within 2 weeks prior to screening, or severe infection (e.g., pneumonia, cellulitis, bone, or joint infections) requiring hospitalization or treatment with intravenous antibiotics within 8 weeks prior to screening;6. Co-morbidities or conditions that may compromise assessment of key outcomes or in the opinion of the clinician, limit the ability of the patient to comply with the protocol;7. Treatment with any of the following anti-cancer therapies prior to the first dose of study treatment:a) Radiation therapy, surgery or tumour embolization within 14 days prior to the first dose of study treatment; palliative radiotherapy (for analgesia) is acceptable only if the irradiated field does not include target lesions;b) Immunotherapy within 28 days prior to the first dose of study treatment;c) Chemotherapy, biologic therapy, or hormonal therapy within 14 days or 5 halflives of a drug prior to the first dose of study treatment or until recovery from previous therapy (whichever is longer);8. Any unresolved toxicity (>CTCAE grade 2) from previous anti-cancer therapy. Subjects with irreversible toxicity that is not reasonably expected to be exacerbated by the investigational product may be included (e.g., hearing loss, peripheral neuropathy);9. Any significant organ dysfunction or clinically significant laboratory abnormalities that place the subject at unacceptable risk for participation in a trial of an immunomodulatory therapy in the judgment of the investigator, within 6 months prior to screening;10. Hospitalization due to an acute cardiovascular event, cardiovascular illness, or cardiovascular surgery within 6 months of screening;11. Uncontrolled hypertension (systolic blood pressure > 160 mm Hg and / or diastolic blood pressure of > 100 mg Hg at screening) or uncontrolled diabetes at screening;12. Administration of any investigational treatment within the indicated washout period prior to receiving the first dose of study treatment:a) Live viral or bacterial vaccination within 28 days;PCT / US2026 / 027788 12 May 2026 (12.05.2026)Attorney Ref. No. 0094-0218W01b) Injectable or oral corticosteroids (greater or equal to daily dose of 20 mg equivalent of prednisone) within 28 days;c) Received another biological agent (e.g., monoclonal antibodies), including immune checkpoint blockades, within 28 days;d) Concurrent participation in an interventional trial with another pharmacologic agent (Observational studies are permitted);e) Participated in an interventional clinical trial within 4 weeks or 5 half-lives of a drug (whichever is longer);f) Radiation therapy, surgery or tumour embolization within 14 days. Palliative radiotherapy (for analgesia) is acceptable only if the irradiated field does not include target lesions;g) Chemotherapy, biologic therapy, or hormonal anticancer therapy within 14 days or 5 half-lives of a drug or until recovery from previous therapy (whichever is longer).13. Symptomatic CNS metastasis or leptomeningeal disease from underlying sarcoma, unless the participant has a stable neurological function, on stable doses of steroids / anti- epileptics over 4 weeks, and with no evidence of CNS progression within 12 weeks prior to screening;14. Concurrent or a past history of another malignancy prior to molecular screening with a less favourable prognosis than the index malignancy are permitted to participate, except for:a) adequately treated skin cancers (including basal cell carcinoma, squamous cell carcinoma squamous cell carcinoma), superficial transitional cell carcinoma of the bladder, or carcinoma of cervix uteri, or;b) other solid or haematological malignancies determined to be free of progressive and metastatic disease at the time of screening.15. Pregnancy, lactation, or inadequate contraception. Women must be post-menopausal, infertile, or use a reliable means of contraception. Women of childbearing potential must have a negative pregnancy test done within 7 days prior to registration. Men must have been surgically sterilised or use a (double if required) barrier method of contraception.Treatment Plan
[0140] Tildrakizumab was administered by subcutaneous injection at 200 mg every 4 weeks (28-day cycles) until disease progression was documented, the patient experienced anPCT / US2026 / 027788 12 May 2026 (12.05.2026)Attorney Ref. No. 0094-0218W01intolerable toxicity, or withdrew for other reasons. Treatment beyond progression was at the discretion of clinicans during the study.
[0141] Treatment was administered according to protocol and only was withheld during adverse events with a severity of Grades 3-4. Treatment was not restarted until the adverse event resolved to Grades 0-1 at investigator's discretion. Day 1 treatment only was delayed by a maximum of 14 days. Beyond 14 days, treatment was discontinued.
[0142] Patients that experienced suspected drug-related adverse events paused treatment until the symptoms resolved. If the study medication was re-introduced and symptoms reappeared, the study medication was discontinued for the patient permanently. No dosing reductions were allowed in this study.
[0143] Treatment after discontinuation of study treatment was at the discretion of the clinician. If patients were responsive to treatment at the end of the study, they were provided with ongoing treatment until the product was publicly available.Concomitant Medications
[0144] Concomitant medications are considered therapies considered necessary to the patient's wellbeing, including antiemetics, antidiarrheals, anti-inflammatory agents, and analgesics.
[0145] Palliative radiation for patients who develop urgent local complications in previously documented sites of disease, treatment with non-conventional therapies (e.g., herbs or acupuncture), and vitamin / mineral supplements were acceptable provided that they do not interfere with study endpoints. Any treatments with anti-cancer indications, including other investigational treatments, traditional / altemative medicines with anti-cancer properties, and live vaccines warranted immediate removal from the study.
[0146] Medication compliance was evaluated at each clinic visit by standard compliance assessments to determine the actual dose taken.Discontinuation of Study Treatment
[0147] Table 3 outlines reasons requiring that the study treatment be permanently discontinued.Table 3. Reasons for Discontinuation of Study1. Study endpoint is reached by any participant (e.g., progressive disease);PCT / US2026 / 027788 12 May 2026 (12.05.2026)Attorney Ref. No. 0094-0218W012. Unacceptable toxicity as determined by the patient or site investigator or as defined by the protocol guidelines for dose modifications;3. The investigator deteremined that the continuation of treatment is not in the patient's best interest;4. Occurrence of an exclusion criterion affecting patient safety, e.g., pregnancy or psychiatric illness;5. Required use of a concomitant treatment that is not permitted, as defined in the protocol (see Concomitant Medications);6. Failure to comply with the protocol, e.g., repeatedly failing to attend scheduled assessments;7. The patient declined further study treatment, or withdrew their consent to participate in the study.
[0148] Patients that stopped study treatment prior to the recommended treatment plan were requrested to continue follow-up visits according to protocol. If participants requested to stop study visits, they were requested to allow their ongoing health status to be periodically reviewed by continued study visits, phone contact, general practitioner, medical records, state-based cancer registries, and / or the national mortality registry (AH4W).Study Endpoints
[0149] The primary endpoints of clinical activity of tildrakizumab were assessed by both size-based ( / .< ., objective tumor response rate [OTRR] assessed by Response Evaluation Criteria in Solid Tumors, RECIST) and metabolic-based assessment criteria (PET Response Criteria in Solid Tumors, PERCIST). The use of of both modalities provided clarity regarding antitumor activities early in treatment of sarcomas, whereas reduction of metabolic activities would strongly indicate biological activities of IL-23 targeting therapy in vivo, independent of objective tumor response.
[0150] Pre-clinical data has shown synergism in combination with liposomal doxorubicin, which can be purused following the presence of an antitumor effect of Tildrakizumab in the trial.Assessment PlanTable 4 outlines the Schedule of Assessments for this study.PCT / US2026 / 027788 12 May 2026 (12.05.2026)Attorney Ref. No. 0094-0218W01Table 4. Schedule of AssessmentsScreening On FollowTreatment up afterend oftreatmentWithin 14 Every 8-weekly Other 30 days Every 8 Every 12 days prior cycle (every 2 after last weeks (±14 weeks (±14 to before cycles) dose (± 7 days) until days) post registration treatment from days) progression5progression (up to 3 treatmentdays (±7 days)prior)Confirmation Xreport fromMTBInformed Xconsent1Clinical X X Xassessment2HBV serology XandQuantiFERON- TBHematology X X(FBC,Coagulationprofiles)Biochemistry X X(includingUEC, LFT,CMP)8Concomitant At timemedications of SAEreportingImaging (FDG- X4- X XPEC / CT)3Pregnancy test XAdverse events X XPCT / US2026 / 027788 12 May 2026 (12.05.2026)Attorney Ref. No. 0094-0218W01Blood for X (for 6 Every 3 Xresearch cycles) cyclesaftercycle 6Research X C3D1biopsy (archival) (onstudy,required)Quality of life X Xassessments6Pain scale7X X XSurvival and X X anticancertreatments’Consent may be collected up to 28 days prior to registration;2Patient performance status will include ECOG performance score;imaging should be conducted using FDG-PET coregistered with a diagnostic CT (chest, abdomen, and pelvis plus region-specific imaging if the target lesion is located outside the coverage of diagnostic scan); imaging, if available, can be dated less than or equal to 21 days prior to registration;5If patient has come off treatment for any reason other than progression, specificed assessmens will continue in follow up at 8 weekly intervals until progression;6EORTC QLQ-C30;7Pain scale- use the Brief Pain inventory for patients with symptomatic disease as appropriate;8Abbreviations: FBC- full blood count; UEC- urea, electrolyte, serum creatinine; LFT- liver function tests; CMP- calcium, magnesium, and phosphate.Details of Assessments
[0151] Tissue collection, blood collection, and FDG-PET response all were recorded as a means to assess study treatment.
[0152] Tissue collection consisted of either baseline archival tissue collections or biopsy collections. Archival tissues were formalin-fixed, paraffin embedded diagnostic material sourced from a pathologist. Archival tissues were collected on subsequent visits unless the sample contained insufficient tissue for molecular screening.
[0153] Mandatory tissue biopsies were collected on day 1 of cycle 3 (C3D1) or within 30 days of the last dose (if a patient came off treatment prior to cycle 3) if diagnostic core biopsy of tumor tissue was able to be conducted. Biopsies were collected within + / - 14 days of C3D1.PCT / US2026 / 027788 12 May 2026 (12.05.2026)Attorney Ref. No. 0094-0218W01
[0154] Peripheral blood collections (30 mL) were obtained from each participant at baseline, during treatment on day 1 of each cycle (prior to administration of tildrakizumab) for six cycles followed by every 3 cycles from cycle 6 (i.e., next collection will be cycle 9), and 30 days after the end of treatment. Blood collected prior to start of cycle 1 can serve as a baseline reading.
[0155] Measurement of FDG-PET response was completed by a dedicated PET specialist using standardized uptake values (SUVmax) for each study lesion. Up to 3 lesions may be reported on each patient. Grading of FDG-PET response was evaluated by the guidelines outlined in Table 5.Table 5. Coding of FDG-PET ResponseStable disease is defined as no measurable change in SUVmax comparing after with before treatment;A minor partial response will be defined as > 25% and < 50% reduction in SUVmax;A major partial response as > 50% and < 100% reduction in SUVmax;A complete response is defined as a 100% reduction in SUVmax.Follow-up After Treatment
[0156] Partipants were followed up for at least 30 days following end of treatment for new adverse events and to follow up any adverse events that were ongoing at the end of treatment visit.
[0157] Patients were followed up for overall survival or subsequent anticancer treatments at 8 weekly intervals until progression (if treatment stopped for reasons other than progression) and at 12 weekly intervals post progression. The data was collected at clinic visits or by phone, depending on patient convenience and health. Date of death was collected by accessing medical records, state-based cancer registries, and / or the national mortality registry (AIHW).Study Treatment Supply
[0158] Tildrakizumab solution for injection (100 mg / mL) is supplied in a ready -to-use 1 mL prefilled glass syringe with safety device or prefilled syringe wholly contained within an auto-injector.PCT / US2026 / 027788 12 May 2026 (12.05.2026)Attorney Ref. No. 0094-0218W01
[0159] Each prefilled syringe contains tildrakizumab solution and the following inactive ingredients: 0.496 mg L-Histidine, 1.42 mg L-Histidine Hydrochloride Monohydrate, 70 mg Sucrose, and 0.5 mg Polysorbate 80.Outcomes
[0160] Tertiary and correlative measures were collected throughout the duration of the study. Translational research studies included identifying biomarkers that are prognostic and / or predictive of response to treatment, safety, and resistance to study treatment (associations of biomarkers with clinical outcomes). Studies included the following:1) The effects of single agent tildrakizumab on immune infiltrates and activation signatures within the tumor;2) Measuring immunologic responses in peripheral samples (cytokine bead arrays, and immunophenotyping of leukocytes by flow cytometry);3) Evaluation of baseline tumour characteristics using immunohistochemistry including, but not limited to CD3, CD4, CD8, CD1 A, CD68;4) Nanostring™ transcript profiling of immune related inflammatory signatures including downstream targets of IL-23;5) Phenotyping by multicolour flow cytometry of immune cell subsets PBMC pre and post treatment; and6) Cytokine levels and soluble immune factors in bloods including IL23.
[0161] Since the identification of new biomarkers correlating with disease activity and the efficacy or safety of treatment is rapidly evolving, the definitive list of biomarkers remains to be determined.Translational and Correlative Studies
[0162] The translational experiments collaboratively provided orthogonal experiments to validate anti-tumor effects seen in this study and similarly investigated the reason for lack of activities. Specifically, correlative science in this study focused on the effects of single agent tildrakizumab on immune infiltrates and activation signatures within the tumor. Additional correlative study includes the following:1. measuring immunologic responses in peripheral blood samples (cytokine bead arrays, and immunophenotyping of leukocytes by flow cytometry);2. baseline tumor IHC (CD3, CD4, CD8, CD1 A, CD68);PCT / US2026 / 027788 12 May 2026 (12.05.2026)Attorney Ref. No. 0094-0218W013. Nanostring™ transcript profiling of 128 genes related to inflammatory signatures including downstream targets of IL-23;4. immunophenotyping by flow cytometry will be conducted in PBMC pre and post Tx tildrakizumab CD4+, CD8+ T-cells, T-reg cell, B-cells, NK, NKT dendritic cells, macrophages, myeloid derived suppressor cells;5. expression of IL23 within these subsets and PD1, Ki67, IFNG, IL2 TNF; and 6. analysis of cytokine levels and soluble immune factors including IL6, IL10, IL8, and IL23 and IFNG in plasma pre- and post- treatments.3. ResultsPatient demographic and clinical characteristics
[0163] The single-arm, phase 2 trial enrolled 32 patients > 18 years (ECOG 0-2) with treatment-refractory bone (n=16) or soft tissue sarcomas (STS) (n=16) from the Australian MoST study. Patients received tildrakizumab 200 mg subcutaneously every 4 weeks until progression or unacceptable toxicity. The primary endpoint was a composite of objective tumor response (OTR, RECIST vl .1) or time-to-progression ratio (TTPr >1.3 versus prior line), where > 3 of 16 patients in either cohort would indicate activity. Secondary endpoints were progression-free survival (PFS), overall survival (OS), and safety. Exploratory endpoints included FDG-PET metabolic response and correlative studies investigating immune markers in paired tumour biopsies and bloods before and on treatment.
[0164] Of the total of 32 patients (16 / cohort) enrolled, no organ transplant recipients (OTRs) were observed in the study. The Time to Progression Ratio > 1.3 occurred in 1 bone and 3 soft tissue sarcoma (STS) patients. The best responses were stable disease in 4 / 16 (25%) of bone patients and 8 / 16 (50%) of STS patients. The median progression-free survival (PFS) was 1.7 (95% CI 1.6-2.0) and 3.3 months (1.7-3.8), and the median overall survival (OS) was 9.7 (3.6-11.5) and 15.0 months (10.0-22.4), for bone and STS cohorts, respectively. Five patients showed > 25% reduction in SUVmax on FDG-PET.
[0165] Tildrakizumab was well tolerated. A total of 4 patients experienced unrelated grade 3 / 4 AEs. Assessment of pretreatment and ongoing treatment biopsies demonstrated that tildrakizumab altered the tumour microenvironment, downregulated oncogenic transcription factors (FOS, EGR1, STAT3, etc.), modulated immune regulators (ICOSLG), and induced systemic immunomodulation characterised by shifts in T cell, monocyte, and NK cell populations.PCT / US2026 / 027788 12 May 2026 (12.05.2026)Attorney Ref. No. 0094-0218W01Bibliography
[0166] Beck et al., "Profile of tildrakizumab-asmn in the treatment of moderate-to-severe plaque psoriasis: evidence to date," Psoriasis (AuckL) 8: 49-58 (2018).
[0167] Fu et al., "Tumor-associated Macrophage-derived Interleukin-23 Interlinks Kidney Cancer Glutamine Addiction with Immune Evasion," Eur Urol. 75(5): 752-63 (2019).
[0168] Jones, "Dendritic Cells Drive Osteosarcomagenesis through Newly Identified Oncogene and Tumor Suppressor," Cancer Discov. 9(11): 1484-86 (2019).
[0169] Kansara et al., "Translational biology of osteosarcoma," Nat. Rev. Cancer 14(11): 722-35 (2014).
[0170] Kansara etal., "Infiltrating Myeloid Cells Drive Osteosarcoma Progression via GRM4 Regulation of IL23," Cancer Discov . 9(11): 1511-19 (2019).
[0171] Langowski et al., "IL-23 promotes tumour incidence and growth," Nature 442(7101): 461-65 (2006).
[0172] Langowski et al., "Swords into plowshares: IL-23 repurposes tumor immune surveillance," Trends ImmunoX. 28(5):207-12 (2007).
[0173] Li etal., "Interleukin 23 promotes hepatocellular carcinoma metastasis via NF-kappa B induced matrix metalloproteinase 9 expression," PLoS One 7(9): e46264 (2012).
[0174] Mease etal., "LB0002 Randomised, Double-Blind, Placebo-Controlled, Multiple-Dose, Phase 2b Study to Demonstrate the Safety and Efficacy of Tildrakizumab, A High-Affinity Anti-Interleukin-23pl9 Monoclonal Antibody, in Patients with Active Psoriatic Arthritis," Ann. Rheum. Dis. 78(2): 78-79 (2019).
[0175] Nie et al., "Tumor-promoting effect of IL-23 in mammary cancer mediated by infiltration of M2 macrophages and neutrophils in tumor microenvironment," Biochem. Biophys. Res. Commun. 482(4): 1400-06 (2017).
[0176] Reich etal., "Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials," Lancet 390(10091): 276-88 (2017).
[0177] Reich etal., "Safety of guselkumab in patients with moderate-to-severe psoriasis treated through 100 weeks: a pooled analysis from the randomized VOYAGE 1 and VOYAGE 2 studies," Br. J. Dermatol. 180: 1039-49 (2019).
[0178] Tawbi et al., "Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single- arm, open-label, phase 2 trial," Lancet Oncol.18(11):1493-501 (2017).PCT / US2026 / 027788 12 May 2026 (12.05.2026)Attorney Ref. No. 0094-0218W01
[0179] Teng et al., "IL-23 suppresses innate immune response independently of IL-17A during carcinogenesis and metastasis," roc. Natl. Acad. Set. U.S.A. 107(18): 8328-33 (2010).
[0180] Teng et al., "Opposing roles for IL-23 and IL-12 in maintaining occult cancer in an equilibrium state," Cancer Res. 72(16): 3987-96 (2012).
[0181] Teng et al., "IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases," Nat. Med. 21(7): 719-29 (2015).
[0182] U.S. Food and Drug Administration, ILUMYA prescribing information, https: / / www.accessdata.fda.gov / drugsatfda docs / label / 2018 / 761067sQ001bl.pdf (last revised 03 / 2018).
[0183] Having described the subject matter of the disclosure in detail and by reference to specific embodiments thereof, it will be apparent that modifications and variations are possible without departing from the scope of the claimed subject matter.
Claims
Attorney Ref. No. 0094-0218W01WHAT IS CLAIMED IS:Claim 1 : A method of treating sarcoma in a patient in need thereof, comprising administering a pharmaceutical composition to the patient, wherein the pharmaceutical composition comprises an anti-IL-23pl9 antibody or antigen binding fragment thereof.Claim 2: The method of Claim 1, wherein the sarcoma is advanced osteosarcoma or soft tissue sarcoma.Claim 3: The method of Claim 1, wherein the anti-IL-23pl9 antibody or antigen binding fragment thereof is the anti-IL-23pl9 antibody huml3B8-b.Claim 4: The method of Claim 3, wherein huml3B8-b comprises:(a) a light chain polypeptide comprising the amino acid sequence of SEQ ID NO: 1, and(b) a heavy chain polypeptide comprising the amino acid sequence of SEQ ID NO:
2. Claim 5: The method of Claim 1, wherein a therapeutically effective amount of the pharmaceutical composition is administered to the patient.Claim 6: The method of Claim 1, wherein a first dose of the pharmaceutical composition is administered to the patient at Week 0.Claim 7: The method of Claim 6, wherein the first dose of the pharmaceutical composition comprises about 100 mg or about 200 mg of the anti-IL-23pl9 antibody or antigen binding fragment thereof, and wherein the anti-IL-23pl9 antibody or antigen binding fragment thereof is optionally the anti-IL-23pl9 antibody huml3B8-b.Claim 8: The method of Claim 6, wherein a second dose of the pharmaceutical composition is administered to the patient after the first dose of the pharmaceutical composition is administered to the patient.Claim 9: The method of Claim 8, wherein the second dose of the pharmaceutical composition comprises about 100 mg or about 200 mg of the anti-IL-23pl9 antibody or antigen binding fragment thereof, and wherein the anti-IL-23pl9 antibody or antigen binding fragment thereof is optionally the anti-IL-23pl9 antibody huml3B8-b.Claim 10: The method of Claim 8, wherein the second dose of the pharmaceutical composition is administered to the patient about 4 weeks after the first dose of the pharmaceutical composition is administered to the patient.Attorney Ref. No. 0094-0218W01Claim 11 : The method of Claim 8, wherein one or more subsequent doses of the pharmaceutical composition are administered to the patient after the second dose of the pharmaceutical composition is administered to the patient.Claim 12: The method of Claim 11, wherein the one or more subsequent doses of the pharmaceutical composition comprise about 100 mg or about 200 mg of the anti-IL-23pl9 antibody or antigen binding fragment thereof, and wherein the anti-IL-23pl9 antibody or antigen binding fragment thereof is optionally the anti-IL-23pl9 antibody huml3B8-b. Claim 13: The method of Claim 1, wherein the one or more subsequent doses of the pharmaceutical composition are administered to the patient about every 4 weeks after the previous dose of the pharmaceutical composition is administered to the patient.Claim 14: The method of Claim 11, wherein the pharmaceutical composition is administered to the patient for at least up to about 12 weeks, for at least up to about 16 weeks, for at least up to about 20 weeks, for at least up to about 24 weeks, for at least up to about 28 weeks, for at least up to about 32 weeks, for at least up to about 36 weeks, for at least up to about 40 weeks, for at least up to about 44 weeks, for at least up to about 48 weeks, for at least up to about 52 weeks, or for more than at least up to about 52 weeks.Claim 15: The method of any one of Claims 1 to 14, wherein the pharmaceutical composition is a stable solution formulation.Claim 16: The method of Claim 15, wherein the stable solution formulation comprises a buffer containing L-histidine and L-histidine hydrochloride, pH 6.0±0.3, polysorbate 80, and sucrose to render the solution isotonic.Claim 17: The method of Claim 16, wherein the stable solution formulation comprises 0.05% (w / v) polysorbate 80 and 7% (w / v) sucrose.Claim 18: The method of any one of Claims 1 to 14, wherein the pharmaceutical composition is administered to the patient subcutaneously.Claim 19: The method of Claim 18, wherein the pharmaceutical composition is administered to the patient by subcutaneous injection.Claim 20: The method of any one of Claims 1 to 14, wherein the pharmaceutical composition is administered to the patient using a prefilled syringe or auto-injector device, intravenous (IV) bag, prefilled ampule, single dose vial, or wearable device.Attorney Ref. No. 0094-0218W01Claim 21 : The method of any one of Claims 1 to 14, wherein the patient has stable disease following treatment.Claim 22: The method of any one of Claims 1 to 14, wherein treatment results in expression of one or more oncogenic transcription factors is downrelugated in the patient, one or more immune regulators is modulated in the patient, and / or population shifts in one or more of T cells, monocytes, and / or NK cells in the patient.Claim 23 : The method of Claim 22, wherein the one or more oncogenic transcription factors is FOS, EGR1, and / or STAT3.Claim 24: The method of Claim 22, wherein the one or more immune regulators is ICOSLG. Claim 25: The method of any one of Claims 1 to 14, wherein the patient has a time-to-progression ratio (TTPr) of at least 1.3 following treatment.Claim 26: The method of any one of Claims 1 to 14, wherein the patient has an at least 25% reduction in Maximum Standardized Uptake Value (SUVmax) on fluorodeoxy glucose Positron Emission Tomography (FDG-PET) following treatment.Claim 27: The method of any one of Claims 1 to 14, wherein treatment results in progression-free survival (PFS) of between 1.7 and 3.3 months.Claim 28: The method of any one of Claims 1 to 14, wherein treatment results in overall survival (OS) of between 9.7 and 15.0 months.Claim 29: The method of any one of Claims 1 to 14, wherein administration of the pharmaceutical composition is associated with minimal or no serious adverse events (SAEs) in the patient.Claim 30: The method of any one of Claims 1 to 14, wherein administration of the pharmaceutical composition is associated with minimal or no treatment emergent adverse events (TEAEs) in the patient.Claim 31 : The method of any one of Claims 1 to 14, wherein administration of the pharmaceutical composition results in the patient experiencing no increase in treatment emergent adverse events (TEAEs) or severe adverse events (SAEs) for at least up to about 12 weeks, for at least up to about 16 weeks, for at least up to about 20 weeks, for at least up to about 24 weeks, for at least up to about 28 weeks, for at least up to about 32 weeks, for at least up to about 36 weeks, for at least up to about 40 weeks, for at least up to about 44Attorney Ref. No. 0094-0218W01weeks, for at least up to about 48 weeks, for at least up to about 52 weeks, or for more than at least up to about 52 weeks.
